Dynavax Technologies Corp.

NASDAQ:DVAX

10.27

+0.11 (+1.08%)

4:20:00 PM EDT: $10.27 0.00 (0.00%)

Market Cap (Intraday)	1.25B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	19.38

See more stats

Estimates Current Quarter

Revenue	$85.91 Million
Adjusted EPS	$0.10

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Dynavax Technologies Corp. Stock, NASDAQ:DVAX

2100 Powell Street, Suite 720, Emeryville, California 94608

United States of America

Phone: +1.510.848.5100

Number of Employees: 405

http://www.dynavax.com

Description

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.